Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular AMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT03313401
What this trial is testing

Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration

Who this might be right for
Age Related Macular Degeneration
Ulucanlar Eye Training and Research Hospital 34
Testing effectiveness (Phase 2)Looking for participantsNCT06141460
What this trial is testing

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
Shanghai Refreshgene Technology Co., Ltd. 48
Post-approval studies (Phase 4)Looking for participantsNCT04853251
What this trial is testing

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Who this might be right for
Neovascular Age-related Macular Degeneration
Genentech, Inc. 188
Not applicableStudy completedNCT03680326
What this trial is testing

Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration

Who this might be right for
Vitreomacular Interface
Hospital Hietzing 43
Post-approval studies (Phase 4)UnknownNCT01669447
What this trial is testing

Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis

Who this might be right for
Degeneration of Macula and Posterior Pole
Osias Francisco de Souza 20
Large-scale testing (Phase 3)Study completedNCT04450329
What this trial is testing

Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
Samsung Bioepis Co., Ltd. 449
Testing effectiveness (Phase 2)Ended earlyNCT04684394
What this trial is testing

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular DegenerationRetinal DiseaseRetinal Degeneration+1 more
Gemini Therapeutics, Inc. 50
Not applicableStudy completedNCT04632056
What this trial is testing

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 329
Early research (Phase 1)Not Yet RecruitingNCT07406438
What this trial is testing

To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
Shenzhen Kexing Pharmaceutical Co., Ltd. 48
Not applicableEnded earlyNCT05112835
What this trial is testing

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 302
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05210803
What this trial is testing

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 116
Testing effectiveness (Phase 2)Study completedNCT01535950
What this trial is testing

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age-elated Macular Degeneration (Wet AMD)Exudative Macular Degeneration
Novartis Pharmaceuticals 43
Large-scale testing (Phase 3)Study completedNCT02462486
What this trial is testing

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Who this might be right for
Macular Degeneration
Allergan 949
Testing effectiveness (Phase 2)Looking for participantsNCT05197270
What this trial is testing

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
4D Molecular Therapeutics 215
Testing effectiveness (Phase 2)Study completedNCT00527423
What this trial is testing

Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD

Who this might be right for
Macular Degeneration
Regeneron Pharmaceuticals 157
Large-scale testing (Phase 3)UnknownNCT00370370
What this trial is testing

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
Shahid Beheshti University of Medical Sciences
Post-approval studies (Phase 4)Study completedNCT01464723
What this trial is testing

Study EvAluating Genotypes While Using Lucentis 2

Who this might be right for
Age-Related Macular Degeneration
University of California, San Diego 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT05769153
What this trial is testing

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Alcon Research 139
Post-approval studies (Phase 4)UnknownNCT00354445
What this trial is testing

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Who this might be right for
Age-Related Macular Degeneration (AMD)
Eyetech Pharmaceuticals 1,000
Not applicableStudy completedNCT03833830
What this trial is testing

Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment

Who this might be right for
Neovascular Age-related Macular Degeneration
Dr. med. Katja Hatz 40
Next Page